At the same time, Cav1.2 and Cav1.3 are expressed in midbrain dopaminergic neurons and several studies suggest a neuroprotective effects of LTCC blockers in Parkinson’s disease,22, 88 which further emphasizes the possibility that inhibition of Cav1.2 may be of therapeutic value in brain disorders that manifest at later stages in life. The gene discussed is CACNA1C; the disease is Parkinson disease.